For deeper background on the investigational oral agent, see Orforglipron Pill
Dr Christian Hendershot, director of the clinical and translational addiction research programme at the University of North Carolina at Chapel Hill, USA, said: We know that drugs in this class are remarkably effective for several important health outcomes many of which can influence longevity and quality of life.
Of course, we have no experience on how people with immune-related or inflammatory disease or individuals, who are also taking immunosuppressive agents, will fare with long term GLP-1 use, and this must be studied. In this sense, the classs history of use over the past 20 years could be a great asset, according to Wright
The SURMOUNT-4 trial demonstrated that participants who achieved significant weight loss on tirzepatide and then continued treatment maintained their weight loss, while those switched to placebo regained substantial weight